9th Monoclonal Antibodies Americas Conference
16th July 2012 — 18th July 2012
Highlighting the pathways for growth, next-generation technologies and addressing challenges in the industry 16th - 18th July 2012, Boston, USA
Monoclonal antibodies remain the single most important product group driving the biopharmaceutical industry’s development. Total sales of mAb therapies in 2010 amounted to $44.6bn, which represented 42% of the total biologics market, over 4% of the total pharmaceutical market, and is double last year's figure¹. Majority of the mAbs are marketed for the treatment of cancer and autoimmune disorders (90%); they generated total revenue of $40.15bn in 2010.
Continued steady growth in sales is expected for the period 2010-2015 at 6.9% per year, which suggests total annual revenue in 2015 - $62.32bn. Main drivers will remain newly approved cancer treatment and greater mAbs use among autoimmune disorder patients.
Versatility of monoclonal antibodies and their obvious advantages over conventional drugs (e.g. safe for healthy cells) ensure pharmaceutical and biotechnological companies invest heavily into their research and development. Complexity of production, tough regulations, costliness and approaching competition from biosimilars on the other hand suggest there are numerous issues to be resolved and discussed.
The first day of the conference is designed to cover the latest research in the field first, providing updates on mAbs in clinical testing, their application and advancements in safety. Day two will focus more on the production side, with topics discussing next-generation technologies, threats from biosimilars through to key regulatory issues.
There is a subject yet unaddressed by other conferences: administration methods. Currently mAbs are administered intravenously, however, there’s growing research and attempts to develop alternative methods (e.g. oral). This is a key area that will be addressed during this event.
Why you should attend?
This visiongain conference is designed to highlight the pathways for growth and address the challenges faced by the industry, while at the same time act as a networking platform for leading researchers and developers. In addition to learning about the latest clinical advancements and breakthroughs, you will have an opportunity to:
• Identify key advances in antibody technology: nanobodies, conjugates, scFvs, and BiTEs
• Discover new therapeutic applications in oncology, autoimmune disorders and ophthalmology
• Gain insight into future for biosimilar mAbs and how they might affect market share
• Investigate the application of phage display libraries and screening techniques to identify new target antigens.
• Review optimised platform approaches to the downstream processing of monoclonal antibodies
• Learn about current clinical and preclinical antibody developments
• Hear about breakthroughs in the monoclonal IgG purification techniques
• Examine how patent expiry will affect access to the antibody engineering technologies
• Learn strategies to navigate through the regulatory framework
• Keep up-to-date by learning advances in the next-generation single-use technology
• Explore alternative administration methods for antibody therapies
• Assess opportunities for financing of mAb therapies
• Network with representatives and scientists from the leading pharmaceutical companies.
Who should attend?
VPs, Directors, Heads, Managers of:
• Antibody development
• CNS autoimmune and inflammatory disease research
• Preclinical/clinical research and development
• Cell and molecular biology
• Recombinant DNA biotechnology
• Protein/ biochemical antibody engineering
• Arthritis R&D
• Oncology R&D
• Ophthalmology R&D (macular degeneration)
• New product development
• Business development
• Clinical diagnostic
• Contract manufacturing
• Contract research organisations
• Pharmaceutical, biotechnology, chemistry law
• Intellectual property law
Expected Number of Attendees
View Conference Website: 9th Monoclonal Antibodies Americas Conference
Price of Attendance